Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Polysialic Acid-Mediated Activity Measurement of Polysialylated Recombinant Coagulation Factor VIII.

Weber A, Engelmaier A, Siekmann J, Turecek PL.

J Pharm Sci. 2019 Oct 16. pii: S0022-3549(19)30656-2. doi: 10.1016/j.xphs.2019.10.019. [Epub ahead of print]

PMID:
31628921
2.

Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys.

Glantschnig H, Bauer A, Benamara K, Dockal M, Ehrlich V, Gritsch H, Höbarth G, Horling FM, Kopic A, Leidenmühler P, Reipert BM, Rottensteiner H, Ruthsatz T, Schrenk G, Schuster M, Turecek PL, Weber A, Wolfsegger M, Scheiflinger F, Höllriegl W.

J Pharmacol Exp Ther. 2019 Oct;371(1):95-105. doi: 10.1124/jpet.119.260067. Epub 2019 Jul 31.

PMID:
31366602
3.

Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor.

Peyvandi F, Kouides P, Turecek PL, Dow E, Berntorp E.

Blood Rev. 2019 Nov;38:100572. doi: 10.1016/j.blre.2019.04.001. Epub 2019 Apr 3. Review.

4.

Issues complicating precision dosing for factor VIII prophylaxis.

Valentino LA, Turecek PL, Gritsch H, Butenas S, Mann KG.

Transfus Apher Sci. 2018 Aug;57(4):472-479. doi: 10.1016/j.transci.2018.07.007. Epub 2018 Aug 21. Review.

5.

Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol) and Other Therapies Indicated for the Pediatric Population: History and Safety.

Stidl R, Denne M, Goldstine J, Kadish B, Korakas KI, Turecek PL.

Pharmaceuticals (Basel). 2018 Jul 26;11(3). pii: E75. doi: 10.3390/ph11030075.

6.

Sensitive and specific assessment of recombinant von Willebrand factor in platelet function analyzer.

Pekrul I, Kragh T, Turecek PL, Novack AR, Ott HW, Spannagl M.

Platelets. 2019;30(2):264-270. doi: 10.1080/09537104.2017.1420153. Epub 2018 Jan 10.

PMID:
29319374
7.

A bio-inspired method for direct measurement of local wall shear rates with micrometer localization using the multimeric protein von Willebrand factor as sensor molecule.

Bonazza K, Scheichl B, Frank J, Rottensteiner H, Schrenk G, Friedbacher G, Turecek PL, Scheiflinger F, Allmaier G.

Biomicrofluidics. 2017 Aug 30;11(4):044117. doi: 10.1063/1.5000503. eCollection 2017 Jul.

8.

The role of ultralarge multimers in recombinant human von Willebrand factor - a review of physico-and biochemical studies and findings in in vivo models and in humans with von Willebrand disease.

Turecek PL, Spannagl M, Kragh T, Allmaier G, Turecek M, Schrenk G, Gritsch H, Obermann-Slupetzky O, Ewenstein BM, Valentino LA.

Hamostaseologie. 2017;37(S 01):S15-S25. doi: 10.5482/HAMO-17-04-0018. Epub 2017 Dec 28.

PMID:
29582921
9.

Selective functional activity measurement of a PEGylated protein with a modification-dependent activity assay.

Weber A, Engelmaier A, Mohr G, Haindl S, Schwarz HP, Turecek PL.

J Pharm Biomed Anal. 2017 Jan 5;132:207-214. doi: 10.1016/j.jpba.2016.09.045. Epub 2016 Sep 29.

PMID:
27764736
10.

Low ADAMTS-13 activity and the risk of coronary heart disease - a prospective cohort study: the Rotterdam Study.

Sonneveld MA, Kavousi M, Ikram MA, Hofman A, Rueda Ochoa OL, Turecek PL, Franco OH, Leebeek FW, de Maat MP.

J Thromb Haemost. 2016 Nov;14(11):2114-2120. doi: 10.1111/jth.13479. Epub 2016 Oct 3.

11.

A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE.

Turecek PL, Romeder-Finger S, Apostol C, Bauer A, Crocker-Buqué A, Burger DA, Schall R, Gritsch H.

Haemophilia. 2016 Nov;22(6):957-965. doi: 10.1111/hae.13001. Epub 2016 Jun 28.

PMID:
27353010
12.

Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy.

Varadi K, Tangada S, Loeschberger M, Montsch P, Schrenk G, Ewenstein B, Turecek PL.

Haemophilia. 2016 Jul;22(4):615-24. doi: 10.1111/hae.12873. Epub 2016 Feb 15.

PMID:
26879158
13.

PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs.

Turecek PL, Bossard MJ, Schoetens F, Ivens IA.

J Pharm Sci. 2016 Feb;105(2):460-475. doi: 10.1016/j.xphs.2015.11.015. Review.

PMID:
26869412
14.

Low ADAMTS13 activity is associated with an increased risk of ischemic stroke.

Sonneveld MA, de Maat MP, Portegies ML, Kavousi M, Hofman A, Turecek PL, Rottensteiner H, Scheiflinger F, Koudstaal PJ, Ikram MA, Leebeek FW.

Blood. 2015 Dec 17;126(25):2739-46. doi: 10.1182/blood-2015-05-643338. Epub 2015 Oct 28.

PMID:
26511134
15.

Shear-Dependent Interactions of von Willebrand Factor with Factor VIII and Protease ADAMTS 13 Demonstrated at a Single Molecule Level by Atomic Force Microscopy.

Bonazza K, Rottensteiner H, Schrenk G, Frank J, Allmaier G, Turecek PL, Scheiflinger F, Friedbacher G.

Anal Chem. 2015 Oct 20;87(20):10299-305. doi: 10.1021/acs.analchem.5b02078. Epub 2015 Sep 30.

PMID:
26369694
16.

Development, Validation, and Application of a Novel Ligand-Binding Assay to Selectively Measure PEGylated Recombinant Human Coagulation Factor VIII (BAX 855).

Weber A, Engelmaier A, Hainzelmayer S, Minibeck E, Anderle H, Schwarz HP, Turecek PL.

Bioconjug Chem. 2015 Oct 21;26(10):2133-42. doi: 10.1021/acs.bioconjchem.5b00442. Epub 2015 Sep 17.

PMID:
26334218
17.

PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.

Ivens IA, Achanzar W, Baumann A, Brändli-Baiocco A, Cavagnaro J, Dempster M, Depelchin BO, Rovira AR, Dill-Morton L, Lane JH, Reipert BM, Salcedo T, Schweighardt B, Tsuruda LS, Turecek PL, Sims J.

Toxicol Pathol. 2015 Oct;43(7):959-83. doi: 10.1177/0192623315591171. Epub 2015 Aug 3. Review.

PMID:
26239651
18.

Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates.

Stidl R, Fuchs S, Bossard M, Siekmann J, Turecek PL, Putz M.

Haemophilia. 2016 Jan;22(1):54-64. doi: 10.1111/hae.12762. Epub 2015 Jul 29.

19.

Ca(2+) concentration-dependent conformational change of FVIII B-domain observed by atomic force microscopy.

Bonazza K, Rottensteiner H, Schrenk G, Fiedler C, Scheiflinger F, Allmaier G, Turecek PL, Friedbacher G.

Anal Bioanal Chem. 2015 Aug;407(20):6051-6. doi: 10.1007/s00216-015-8778-z. Epub 2015 May 23.

PMID:
26001809
20.

A Flow-Cytometry-Based Approach to Facilitate Quantification, Size Estimation and Characterization of Sub-visible Particles in Protein Solutions.

Lubich C, Malisauskas M, Prenninger T, Wurz T, Matthiessen P, Turecek PL, Scheiflinger F, Reipert BM.

Pharm Res. 2015 Sep;32(9):2863-76. doi: 10.1007/s11095-015-1669-3. Epub 2015 Mar 19.

PMID:
25788448
21.

Development of a lectin binding assay to differentiate between recombinant and endogenous proteins in pharmacokinetic studies of protein-biopharmaceuticals.

Weber A, Minibeck E, Scheiflinger F, Turecek PL.

J Pharm Biomed Anal. 2015 Apr 10;108:21-8. doi: 10.1016/j.jpba.2015.01.047. Epub 2015 Feb 2.

PMID:
25703236
22.

Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.

Turecek PL, Abbühl B, Tangada SD, Chapman M, Gritsch H, Rottensteiner H, Schrenk G, Mitterer A, Dietrich B, Höllriegl W, Schiviz A, Horling F, Reipert BM, Muchitsch EM, Pavlova BG, Scheiflinger F.

Expert Rev Clin Pharmacol. 2015 Mar;8(2):163-77. doi: 10.1586/17512433.2015.1011126. Epub 2015 Feb 8.

PMID:
25660348
23.

The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule.

Valentino LA, Cong L, Enockson C, Song X, Scheiflinger F, Muchitsch EM, Turecek PL, Hakobyan N.

Haemophilia. 2015 Jan;21(1):58-63. doi: 10.1111/hae.12532. Epub 2014 Dec 2.

PMID:
25459309
24.

A novel flow-based assay reveals discrepancies in ADAMTS-13 inhibitor assessment as compared with a conventional clinical static assay.

Grillberger R, Gruber B, Skalicky S, Schrenk G, Knöbl P, Plaimauer B, Turecek PL, Scheiflinger F, Rottensteiner H.

J Thromb Haemost. 2014 Sep;12(9):1523-32. doi: 10.1111/jth.12653. Epub 2014 Jul 29.

25.

Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura.

Grillberger R, Casina VC, Turecek PL, Zheng XL, Rottensteiner H, Scheiflinger F.

Haematologica. 2014 Apr;99(4):e58-60. doi: 10.3324/haematol.2013.100685. Epub 2014 Feb 14. No abstract available.

26.

Visualization of a protein-protein interaction at a single-molecule level by atomic force microscopy.

Bonazza K, Rottensteiner H, Seyfried BK, Schrenk G, Allmaier G, Turecek PL, Friedbacher G.

Anal Bioanal Chem. 2014 Feb;406(5):1411-21. doi: 10.1007/s00216-013-7563-0. Epub 2013 Dec 21.

PMID:
24363113
27.

Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.

Ferrari S, Palavra K, Gruber B, Kremer Hovinga JA, Knöbl P, Caron C, Cromwell C, Aledort L, Plaimauer B, Turecek PL, Rottensteiner H, Scheiflinger F.

Haematologica. 2014 Apr;99(4):779-87. doi: 10.3324/haematol.2013.094151. Epub 2013 Nov 15.

28.

Development of novel treatment options for patients with haemophilia.

Ehrlich HJ, Wong WY, Ewenstein BM, Dockal M, Turecek PL, Gringeri A, Chehadeh H, Löw-Baselli A, Scheiflinger F, Reininger AJ.

Hamostaseologie. 2013;33 Suppl 1:S36-8. Review.

PMID:
24169902
29.

Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B.

Dietrich B, Schiviz A, Hoellriegl W, Horling F, Benamara K, Rottensteiner H, Turecek PL, Schwarz HP, Scheiflinger F, Muchitsch EM.

Int J Hematol. 2013 Nov;98(5):525-32. doi: 10.1007/s12185-013-1448-z. Epub 2013 Sep 24.

PMID:
24061775
30.

Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.

Mannucci PM, Kempton C, Millar C, Romond E, Shapiro A, Birschmann I, Ragni MV, Gill JC, Yee TT, Klamroth R, Wong WY, Chapman M, Engl W, Turecek PL, Suiter TM, Ewenstein BM; rVWF Ad Hoc Study Group.

Blood. 2013 Aug 1;122(5):648-57. doi: 10.1182/blood-2013-01-479527. Epub 2013 Jun 18.

31.

BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation.

Turecek PL, Bossard MJ, Graninger M, Gritsch H, Höllriegl W, Kaliwoda M, Matthiessen P, Mitterer A, Muchitsch EM, Purtscher M, Rottensteiner H, Schiviz A, Schrenk G, Siekmann J, Varadi K, Riley T, Ehrlich HJ, Schwarz HP, Scheiflinger F.

Hamostaseologie. 2012;32 Suppl 1:S29-38.

PMID:
22961422
32.

Microchip capillary gel electrophoresis of multiply PEGylated high-molecular-mass glycoproteins.

Seyfried BK, Marchetti-Deschmann M, Siekmann J, Bossard MJ, Scheiflinger F, Turecek PL, Allmaier G.

Biotechnol J. 2012 May;7(5):635-41. doi: 10.1002/biot.201100407.

PMID:
22407778
33.

Inverse correlation of free and immune complex-sequestered anti-ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura.

Ferrari S, Knöbl P, Kolovratova V, Plaimauer B, Turecek PL, Varadi K, Rottensteiner H, Scheiflinger F.

J Thromb Haemost. 2012 Jan;10(1):156-8. doi: 10.1111/j.1538-7836.2011.04548.x. No abstract available.

34.

Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model.

van Helden PM, Unterthurner S, Hermann C, Schuster M, Ahmad RU, Schiviz AN, Weiller M, Antoine G, Turecek PL, Muchitsch EM, Schwarz HP, Reipert BM.

Blood. 2011 Sep 29;118(13):3698-707. doi: 10.1182/blood-2010-11-316521. Epub 2011 Jun 24.

PMID:
21705497
35.

Structural analysis of the recombinant therapeutic product rFVIII and its PEGylated variants using 2-D DIGE.

Monetti C, Rottensteiner H, Gritsch H, Weber A, Scheiflinger F, Turecek PL.

Electrophoresis. 2011 Jun;32(11):1292-301. doi: 10.1002/elps.201000627. Epub 2011 Apr 26.

PMID:
21520149
36.

Structure and function of a recombinant von Willebrand factor drug candidate.

Turecek PL, Schrenk G, Rottensteiner H, Varadi K, Bevers E, Lenting P, Ilk N, Sleytr UB, Ehrlich HJ, Schwarz HP.

Semin Thromb Hemost. 2010 Jul;36(5):510-21. doi: 10.1055/s-0030-1255445. Epub 2010 Jul 15. Review.

PMID:
20635317
37.

Preclinical testing of human recombinant von Willebrand factor: ADAMTS13 cleavage capacity in animals as criterion for species suitability.

Muchitsch EM, Dietrich B, Rottensteiner H, Auer W, Nehrbass D, Gritsch H, Ehrlich HJ, Turecek PL, Schwarz HP.

Semin Thromb Hemost. 2010 Jul;36(5):522-8. doi: 10.1055/s-0030-1255446. Epub 2010 Jul 14. Review.

PMID:
20632249
38.

Comparison of plasma-derived and recombinant von Willebrand factor by atomic force microscopy.

Seyfried BK, Friedbacher G, Rottensteiner H, Schwarz HP, Ehrlich H, Allmaier G, Turecek PL.

Thromb Haemost. 2010 Sep;104(3):523-30. doi: 10.1160/TH10-02-0081. Epub 2010 Jun 29.

PMID:
20589314
39.

MALDI linear TOF mass spectrometry of PEGylated (glyco)proteins.

Seyfried BK, Siekmann J, Belgacem O, Wenzel RJ, Turecek PL, Allmaier G.

J Mass Spectrom. 2010 Jun;45(6):612-7. doi: 10.1002/jms.1746.

PMID:
20527029
40.

GEMMA and MALDI-TOF MS of reactive PEGs for pharmaceutical applications.

Kemptner J, Marchetti-Deschmann M, Siekmann J, Turecek PL, Schwarz HP, Allmaier G.

J Pharm Biomed Anal. 2010 Aug 1;52(4):432-7. doi: 10.1016/j.jpba.2010.01.017. Epub 2010 Jan 18.

PMID:
20138456
41.

Development of a plasma- and albumin-free recombinant von Willebrand factor.

Turecek PL, Mitterer A, Matthiessen HP, Gritsch H, Varadi K, Siekmann J, Schnecker K, Plaimauer B, Kaliwoda M, Purtscher M, Woehrer W, Mundt W, Muchitsch EM, Suiter T, Ewenstein B, Ehrlich HJ, Schwarz HP.

Hamostaseologie. 2009 Oct;29 Suppl 1:S32-8.

PMID:
19763356
42.

Species-dependent variability of ADAMTS13-mediated proteolysis of human recombinant von Willebrand factor.

Varadi K, Rottensteiner H, Vejda S, Weber A, Muchitsch EM, Turecek PL, Ehrlich HJ, Scheiflinger F, Schwarz HP.

J Thromb Haemost. 2009 Jul;7(7):1134-42. doi: 10.1111/j.1538-7836.2009.03453.x. Epub 2009 Apr 24.

43.

Strategies for recombinant Furin employment in a biotechnological process: complete target protein precursor cleavage.

Preininger A, Schlokat U, Mohr G, Himmelspach M, Stichler V, Kyd-Rebenburg A, Plaimauer B, Turecek PL, Schwarz HP, Wernhart W, Fischer BE, Dorner F.

Cytotechnology. 1999 Jul;30(1-3):1-16. doi: 10.1023/A:1008030407679.

44.

Ethanol dependence of alpha 1-antitrypsin C-terminal Lys truncation mediated by basic carboxypeptidases.

Matthiessen HP, Willemse J, Weber A, Turecek PL, Deiteren K, Hendriks D, Ehrlich HJ, Schwarz HP.

Transfusion. 2008 Feb;48(2):314-20. Epub 2007 Nov 19.

PMID:
18028276
45.

Convenient high-resolution isoelectric focusing (IEF) method for the separation of alpha1-proteinase inhibitor (A1PI) isoforms in A1PI concentrates.

Weber A, Engelmaier A, Owen MC, Schwarz HP, Turecek PL.

J Pharm Biomed Anal. 2007 Sep 21;45(1):107-111. doi: 10.1016/j.jpba.2007.06.006. Epub 2007 Jun 13.

PMID:
17629652
46.

Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy.

Kolarich D, Turecek PL, Weber A, Mitterer A, Graninger M, Matthiessen P, Nicolaes GA, Altmann F, Schwarz HP.

Transfusion. 2006 Nov;46(11):1959-77. Erratum in: Transfusion. 2007 Aug;47(8):1558.

PMID:
17076852
47.

Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells.

Pfistershammer K, Stöckl J, Siekmann J, Turecek PL, Schwarz HP, Reipert BM.

Thromb Haemost. 2006 Sep;96(3):309-16.

PMID:
16953272
48.

Proteomic analysis of UVC irradiation-induced damage of plasma proteins: Serum amyloid P component as a major target of photolysis.

Chan HL, Gaffney PR, Waterfield MD, Anderle H, Peter Matthiessen H, Schwarz HP, Turecek PL, Timms JF.

FEBS Lett. 2006 May 29;580(13):3229-36. Epub 2006 May 6.

49.

In vitro and in vivo anti-retroviral activity of the substance purified from the aqueous extract of Chelidonium majus L.

Gerencer M, Turecek PL, Kistner O, Mitterer A, Savidis-Dacho H, Barrett NP.

Antiviral Res. 2006 Nov;72(2):153-6. Epub 2006 Apr 18.

PMID:
16647765
50.

Comprehensive glyco-proteomic analysis of human alpha1-antitrypsin and its charge isoforms.

Kolarich D, Weber A, Turecek PL, Schwarz HP, Altmann F.

Proteomics. 2006 Jun;6(11):3369-80.

PMID:
16622833

Supplemental Content

Loading ...
Support Center